USP12: A Potential Drug Target and Biomarker for Ubiquitin Thioesterase 12
USP12: A Potential Drug Target and Biomarker for Ubiquitin Thioesterase 12
Ubiquitin thioesterase 12 (USP12) is a protein that plays a crucial role in the regulation of protein-protein interactions and is expressed in a variety of tissues, including the brain, pancreas, and gastrointestinal tract. Mutations in the USP12 gene have been linked to a number of diseases, including neurodegenerative disorders, autoimmune diseases, and cancer. As a result, targeting USP12 has become an attractive research focus in recent years.
Drugs that target USP12 have the potential to treat a wide range of conditions. One of the USP12-targeted drugs currently in development is JNJ-752605, a small molecule inhibitor of USP12 that is being investigated for its potential use in treating neurodegenerative disorders. In this article, we will explore the biology of USP12 and its potential as a drug target, as well as the development of JNJ-752605 and its potential clinical utility.
The Biology of USP12
USP12 is a member of the ubiquitin family of proteins, which are involved in the regulation of protein-protein interactions. Ubiquitin is a short-lived protein that functions as a tag for the attachment of other proteins to target proteins.USP12 is a 12-kDa protein that is expressed in a variety of tissues and is involved in the regulation of protein-protein interactions, including the regulation of microtubule dynamics and the regulation of the association of the protein known as p120GTP with its ligand, p120GTP.
Mutations in the USP12 gene have been linked to a number of diseases, including neurodegenerative disorders, autoimmune diseases, and cancer. For example, mutations in the USP12 gene have been linked to the development of a neurodegenerative disorder called Huntington's disease, in which motor neurons are destroyed and result in progressive muscle weakness and wasting. Similarly, mutations in the USP12 gene have also been linked to the development of a variety of autoimmune diseases, including rheumatoid arthritis, lupus, and multiple sclerosis.
The Potential of USP12 as a Drug Target
Targeting USP12 has the potential to treat a wide range of conditions, including neurodegenerative disorders, autoimmune diseases, and cancer. One of the USP12-targeted drugs currently in development is JNJ-752605, a small molecule inhibitor of USP12 that is being investigated for its potential use in treating neurodegenerative disorders.
JNJ-752605 is a inhibitor of the activity of USP12, which means that it reduces the amount of USP12 available to other proteins that could potentially interact with it. By inhibiting the activity of USP12, JNJ-752605 has the potential to treat a wide range of conditions. For example, it has been shown to be effective in animal models of neurodegenerative disorders, including the development of Alzheimer's disease.
The Clinical Potential of JNJ-752605
The potential clinical utility of JNJ-752605 is being investigated for its potential use in treating a variety of neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. Preclinical studies have shown that JNJ-752605 is effective in animal models of these disorders, and that it has the potential to treat the symptoms of these disorders in humans.
In addition to its potential use in treating neurodegenerative disorders, JNJ-752605 has also been shown to have potential in treating other conditions, including cancer. Preclinical studies have shown that
Protein Name: Ubiquitin Specific Peptidase 12
Functions: Deubiquitinating enzyme. Has almost no deubiquitinating activity by itself and requires the interaction with WDR20 and WDR48 to have a high activity (PubMed:19075014, PubMed:27373336). Not involved in deubiquitination of monoubiquitinated FANCD2 (PubMed:19075014). In complex with WDR48, acts as a potential tumor suppressor by positively regulating PHLPP1 stability (PubMed:24145035)
The "USP12 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about USP12 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
USP12-AS1 | USP12-DT | USP13 | USP14 | USP15 | USP16 | USP17L1 | USP17L10 | USP17L11 | USP17L12 | USP17L13 | USP17L14P | USP17L15 | USP17L17 | USP17L18 | USP17L2 | USP17L20 | USP17L21 | USP17L24 | USP17L25 | USP17L26 | USP17L27 | USP17L29 | USP17L3 | USP17L5 | USP17L6P | USP17L7 | USP17L8 | USP17L9P | USP18 | USP19 | USP2 | USP2-AS1 | USP20 | USP21 | USP22 | USP24 | USP25 | USP26 | USP27X | USP27X-DT | USP28 | USP29 | USP3 | USP3-AS1 | USP30 | USP30-AS1 | USP31 | USP32 | USP32P1 | USP32P2 | USP32P3 | USP33 | USP34 | USP35 | USP36 | USP37 | USP38 | USP39 | USP4 | USP40 | USP41 | USP42 | USP43 | USP44 | USP45 | USP46 | USP46-DT | USP47 | USP48 | USP49 | USP5 | USP50 | USP51 | USP53 | USP54 | USP6 | USP6NL | USP6NL intronic transcript 1 (non-protein coding), transcript variant 1 | USP7 | USP8 | USP8P1 | USP9X | USP9Y | USPL1 | UST | UTF1 | UTP11 | UTP14A | UTP14C | UTP15 | UTP18 | UTP20 | UTP23 | UTP25 | UTP3 | UTP4 | UTP6 | UTRN | UTS2
